Vanda Pharmaceuticals Profit Margin

Vanda Pharmaceuticals (VNDA) currently reports a profit margin of -127.41% as of June 2026. That compares with -32.9% in the prior-year period — down 287.3% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Vanda Pharmaceuticals's profit margin history and peer comparisons.

Vanda Pharmaceuticals's profit margin decreased from -32.9% to -127.41% — a 287.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vanda Pharmaceuticals's profit margin of -127.41% is lower than the Healthcare sector average of 13.89%. That is roughly 1017.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Vanda Pharmaceuticals's current -127.41% should be judged against Healthcare norms (sector average: 13.89%) and against VNDA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -127.41%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Vanda Pharmaceuticals, and consider following VNDA for alerts when major investors trade the stock.